Patients, transplant, and graft characteristics according to the use of ATG in the Cy/Flu/TBI200 regimen for UCBT in adults with hematologic malignancies
| Characteristics . | Non-ATG group (n = 579) . | ATG group (n = 82) . | Total (N = 661) . | P* . |
|---|---|---|---|---|
| Patient related | ||||
| Age at UCBT | ||||
| Median | 52 | 54 | 52 | .068 |
| Range | 18-69 | 19-72 | 18-72 | |
| Male sex, n (%) | 289 (50) | 49 (60) | 338 (51) | .10 |
| Recipient-CMV serostatus at transplant, n (%) | 338 (60) | 54 (67) | 392 (61) | .18 |
| Diagnosis, n (%) | ||||
| Acute leukemias | 294 (51) | 40 (49) | 334 (51) | .009 |
| MDS/MPD or CML | 101 (17) | 25 (31) | 126 (19) | |
| Lymphoproliferative disorders | 184 (32) | 17 (21) | 201 (30) | |
| Disease status at UCBT, n (%) | ||||
| Advanced | 245 (43) | 44 (54) | 289 (44) | .063 |
| CR1/2 | 328 (57) | 38 (46) | 366 (56) | |
| Previous ASCT, n (%) | 180 (32) | 19 (23) | 199 (30) | .12 |
| Graft related | ||||
| Single UCBT, n (%) | 197 (34) | 29 (35) | 226 (34) | .81 |
| HLA compatibility, n (%)† | ||||
| 6/6 or 5/6 | 152 (28) | 21 (30) | 173 (29) | .76 |
| ≤4/6 | 386 (72) | 49 (70) | 435 (72) | |
| ABO incompatibility, n (%) | ||||
| Compatibles/minor | 152 (29) | 10 (20) | 162 (28) | .21 |
| Major | 374 (71) | 39 (80) | 413 (72) | |
| Sex mismatch, n (%) | 187 (33) | 36 (47) | 223 (35) | .013 |
| TNC collected, median (range) | 4.42 (0.41-12.21) | 4.14 (1.99-13.67) | (0.41-13.67) | .51 |
| TNC infused, median (range) | 3.5 (0.38-9.44) | 3.54 (1.1-6.6) | (0.38-9.44) | .95 |
| Characteristics . | Non-ATG group (n = 579) . | ATG group (n = 82) . | Total (N = 661) . | P* . |
|---|---|---|---|---|
| Patient related | ||||
| Age at UCBT | ||||
| Median | 52 | 54 | 52 | .068 |
| Range | 18-69 | 19-72 | 18-72 | |
| Male sex, n (%) | 289 (50) | 49 (60) | 338 (51) | .10 |
| Recipient-CMV serostatus at transplant, n (%) | 338 (60) | 54 (67) | 392 (61) | .18 |
| Diagnosis, n (%) | ||||
| Acute leukemias | 294 (51) | 40 (49) | 334 (51) | .009 |
| MDS/MPD or CML | 101 (17) | 25 (31) | 126 (19) | |
| Lymphoproliferative disorders | 184 (32) | 17 (21) | 201 (30) | |
| Disease status at UCBT, n (%) | ||||
| Advanced | 245 (43) | 44 (54) | 289 (44) | .063 |
| CR1/2 | 328 (57) | 38 (46) | 366 (56) | |
| Previous ASCT, n (%) | 180 (32) | 19 (23) | 199 (30) | .12 |
| Graft related | ||||
| Single UCBT, n (%) | 197 (34) | 29 (35) | 226 (34) | .81 |
| HLA compatibility, n (%)† | ||||
| 6/6 or 5/6 | 152 (28) | 21 (30) | 173 (29) | .76 |
| ≤4/6 | 386 (72) | 49 (70) | 435 (72) | |
| ABO incompatibility, n (%) | ||||
| Compatibles/minor | 152 (29) | 10 (20) | 162 (28) | .21 |
| Major | 374 (71) | 39 (80) | 413 (72) | |
| Sex mismatch, n (%) | 187 (33) | 36 (47) | 223 (35) | .013 |
| TNC collected, median (range) | 4.42 (0.41-12.21) | 4.14 (1.99-13.67) | (0.41-13.67) | .51 |
| TNC infused, median (range) | 3.5 (0.38-9.44) | 3.54 (1.1-6.6) | (0.38-9.44) | .95 |
ASCT, autologous stem cell transplantation; CML, chronic myeloid leukemia; CR1/2, first and second complete remission; MDS/MPD, myelodysplastic syndrome/myeloproliferative neoplasm.
The χ2 test was used for categorical variables, and the Mann-Whitney nonparametric test for continuous variables.
HLA compatibility was analyzed by serology or low-resolution typing level for HLA-A and -B and by allelic (DNA) or high-resolution typing for HLA-DRB1.